Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Inclusion Criteria:

Histologic diagnosis of prostate adenocarcinoma.
Patient must have progressive metastatic prostate cancer despite adequate medical or surgical castration therapy.
Serum testosterone < 50 mg/ml.

Patients who have previously received docetaxel must meet BOTH of the the following criteria:

reason for docetaxel discontinuation must NOT have been progression of disease while receiving drug (i.e. progression of cancer must have been AFTER docetaxel discontinuation) AND
All docetaxel-related toxicities must have resolved to < grade 1 (with the exception of alopecia) and the pt must be eligible by other criteria

Exclusion Criteria:

Use of red blood cell or platelet transfusions within 4 weeks of treatment.
Use of hematopoietic growth factors within 4 weeks of treatment.-Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.
Bone scan demonstrating confluent lesions involving both axial and appendicular skeleton ("superscan").
Prior radiation therapy encompassing >25% of skeleton.Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®).
Platelet count <150,000/mm3.
Absolute neutrophil count (ANC) <2,000/mm3.
Hematocrit <30 percent or Hemoglobin < 10 g/dL.
Abnormal coagulation profile (PT or INR, PTT) > 1.3 x upper limit of normal (unless on therapeutic anticoagulation).
-Serum creatinine >2.5 mg/dL.
AST (SGOT) >2.5x ULN.
Bilirubin (total) >1.5x ULN.
Serum calcium >11 mg/dL.
Active serious infection.
Active angina pectoris or New York Heart Association Class III-IV.
ECOG Performance Status >2.
Life expectancy <6 months.
Deep vein thrombosis and/or pulmonary embolus within 1 month of study entry.
Other serious illness(es) which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
Prior anti-PSMA monoclonal antibody therapy with the exception of ProstaScint®.
Prior investigational therapy within 6 weeks of treatment.
Known history of HIV.
Known history of myelodysplastic syndrome or leukemia